Company Overview
Vanda Pharmaceuticals Inc. operates as a biopharmaceutical company dedicated to the development and commercialization of therapies designed to address significant unmet medical needs globally. Its commercial portfolio currently includes Fanapt, which is utilized for the acute treatment of manic or mixed episodes associated with bipolar I disorder. The company functions within the Healthcare sector, specifically the Biotechnology industry, a space characterized by high research and development costs and long product development cycles. Vanda holds a market capitalization of $416.12M and reported annual revenue of $216.10M over the trailing twelve months, employing a workforce of 533 individuals. These valuation and revenue figures indicate that the company maintains a mid-cap profile typical of specialized biotechnology firms that are actively generating product revenue while still navigating the financial challenges inherent in bringing novel therapies to market.
Financial Health
Over the trailing twelve months, Vanda generated revenue of $216.10M, recorded a net income of $-220,474,000, and reported EBITDA of $-143,058,000. The substantial negative gap between the positive revenue figure and the significantly negative net income reveals a cost structure where operating expenses and other charges heavily outweigh the revenue generated from sales. The company generated free cash flow of $-49,359,000, which indicates a consumption of cash that limits immediate financial flexibility and necessitates access to capital markets or existing reserves to fund ongoing operations. Margin analysis shows a gross margin of 94.0%, reflecting the typical high-cost-of-goods-sold dynamics in biotechnology, contrasted with an operating margin of -70.5% and a profit margin of -102.0% that highlight the heavy burden of overhead costs and R&D expenses. The company holds cash totaling $263.85M against total debt of $12.62M, resulting in a debt-to-equity ratio of 3.86. Despite the high leverage ratio, the balance sheet can be viewed as conservative regarding liquidity risk because the cash position far exceeds the debt obligation. Additionally, the current ratio stands at 2.39, indicating a strong short-term liquidity position where current assets are more than twice the value of current liabilities. Return on Equity is -50.9% and Return on Assets is -16.5%, metrics that reveal management has yet to achieve profitability, reflecting the reality that the company is currently burning capital rather than generating returns on its equity or asset base.
Valuation Assessment
The trailing P/E ratio is N/A due to the negative earnings, while the forward P/E is 35.20. This stark difference between a non-existent trailing multiple and a positive forward multiple implies that the market is pricing in a future trajectory where the company expects to turn profitable within the next fiscal period. The price-to-book ratio is 1.27, indicating that the market values the company at a premium of 27% over its net asset book value. Alternative valuation metrics include a price-to-sales ratio of 1.93 and an EV/EBITDA of -1.19. The positive price-to-sales ratio suggests that investors are willing to pay nearly twice the annual sales revenue for the company, while the negative EV/EBITDA confirms the firm's current lack of earnings power. Regarding trading range, the 52-week high is $9.94 and the 52-week low is $3.81. Without a specific current share price provided in the available facts, the position relative to this range cannot be mathematically calculated, but the wide spread between the high and low demonstrates significant price volatility over the past year. The beta value is 0.61, which indicates that the stock's price volatility is roughly 39% lower than the broader market, suggesting the asset moves less aggressively than the general market index.
Growth & Income
Revenue growth year-over-year stands at 7.6%, while earnings growth is N/A due to the company's current net losses. Because earnings are negative, they cannot grow faster than revenue in the traditional sense of increasing profit; instead, the company is expanding its top line while still working to reduce the losses that suppress the bottom line. The dividend yield is N/A and the payout ratio is 0.0%, indicating that the company does not distribute dividends to shareholders. As a non-dividend payer, Vanda reinvests all available earnings, or rather its remaining cash reserves, back into the business to fund its pipeline and operational needs rather than paying cash returns. The overall growth and income profile is characterized by steady revenue expansion without current profitability or income distribution, typical for a biotechnology firm in a growth phase focused on product commercialization.